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S_mmary Epidermal growth factor receptor (EGFR) overexpression has been associated frequently with
squamous cell carcinomas (SCC) and SCC cell lines. In most cases the level of EGFR on the tumours from
which the cell lines were derived has not been determined, nor have EGFR levels been determined for
xenograft tumours from the cell lines. In this study we determined EGFR expression on a new series of head
and neck SCC (SCCHN)-derived cell lines, which were obtained from tumours representing a spectrum of
malignant progression, and two cell strains derived from erythroplakia premalignant lesions. The level of
EGFR on cell lines was determined by ['UI]EGF competitive binding assays. EGFR levels on some of the
original tumours and xenografts of the cell lines were determined on cryosections by a competitive binding
assay based on ['"I]EGFRI, an EGFR-specific monoclonal antibody. EGFR expression on the tumour
cryosections was compared with expression on cryosections of skin and buccal mucosa. Eight of the ten
tumour cell lines had elevated EGFR. Two of the tumour-derived cell lines and the two erythroplakia-derived
cell strains expressed EGFR at levels similar to that detected on normal keratinocytes in tissue culture. Only
two of the tumours overexpressed EGFR when compared with normal tissue. The other tumours had levels
similar to that detected on the basal layers of skin or buccal mucosa. The xenografts expressed EGFR, as did
the original tumours, even though they were derived from cell lines that displayed significant overexpression of
EGFR. This study suggests that most tumours have a latent potential to overexpress EGFR which is realised
in tissue culture.
The EGFR is frequently, but not necessarily, overexpressed
on SCC-derived cell lines (Wrann & Fox, 1979; Merlino et
al., Cowley et al., 1984, 1986; 1984; Ozanne et al., 1986a;
Prime et al., 1994) and tumours (Hendler & Ozanne, 1984;
Gullick et al., 1986; Ozanne et al., 1986b; Derynck et al.,
1987; Hendler et al., 1989; Ishitoya et al., 1989; Weichsel-
baum et al., 1989; Gullick, 1991; Gorgolis et al., 1992). Its
gene, c-erbB (Downward et al., 1984), is located on
chromosome 7pl2-14 and spans at least 10kb (Haley et
al., 1987). It encodes two mRNAs of 10 and 5 kb (Ullrich et
al., 1984). The EGFR is a phosphoglycoprotein of 170 kDa
(Prigent & Lemoine, 1992). The extracellular domain binds
ligand, which activates the intracellular domain protein
tyrosine kinase. The ligands for the EGFR include epidermal
growth factor (EGF) (Savage et al., 1972), transforming
growth factor alpha (TGF-x) (DeLarco & Todaro, 1978),
heparin-binding epidermal growth factor (HBEGF)
(Higashiyama et al., 1991) and amphiregulin (AR) (Shoyab et
al., 1989). Both non-malignant keratinocytes and squamous
cell carcinomas can produce EGF and TGF-a (Coffey et al.,
1987; Derynck et al., 1987; Yoshida et al., 1990) and
HBEGF (Cook et al., 1991) and thereby may constitute an
autocrine system (Sporn & Todaro, 1985). The first indica-
tion that overexpression might be important to tumour
growth was provided by experiments with the vulval epider-
moid carcinoma-derived cell line, A431, which has 2 x 106
EGFRs per cell. Variants were selected which had fewer
EGFRs. These variants were less tumorigenic than the paren-
tal A431 cells (Santon et al., 1986). Overexpression of EGFR
by SCC cell lines might help them respond to low amounts
of EGF or TGF-a, while inhibition of ligand binding to the
EGFR by EGFR-specific monoclonal antibodies seems to
block the growth of SCC cell lines in tissue culture and
xenografts, which highlights the importance of the EGFR to
the growth of SCC (Masui et al., 1984; Modjtahedi et al.,
1993a, b). Owing to its reported overexpression, the EGFR
has been suggested to be a potential target for diagnosis (Soo
et al., 1987; Divgi et al., 1991) or directed therapy of SCC
(Harris, 1990; Ennis et al., 1991). Although several studies
have indicated that the EGFR is overexpressed on human
SCC, quantitation of the overexpression relies heavily on the
study of SCC-derived cell lines in which the frequency of
significant overexpression is very high (Cowley et al., 1984,
1986). Most studies have relied upon cell lines which have
been isolated under culture conditions unfavourable for the
growth of normal keratinocytes (Easty et al., 1981). Thus,
they may have selected for tumours which express very high
levels of EGFR in vivo; otherwise only a minority of the
tumour cells that overexpress the EGFR would be selected
for growth in culture. A recent study which established cell
lines from oral cavity tumours found that only one out of
eight cell lines overexpressed the EGFR (Prime et al., 1994).
In the present study we have analysed EGFR expression on a
series of cell lines derived from SCCHN under culture condi-
tions favourable for the growth of normal keratinocytes
(Rheinwald & Beckett, 1981). We have also determined
EGFR levels on cryosections of the original tumours and on
xenografts of some of the cell lines.
Materials and methods
Cell culture
All cells were cultured at 37°C in a humidified atmosphere of
5% carbon dioxide in air. A431, EJ and ZR-75-1 cells were
maintained in Dulbecco's modified Eagle medium (DMEM,
Gibco, Paisley, UK), with 10% fetal bovine serum (FBS,
Gibco, Paisley, UK), and supplemented with L-glutamine,
penicillin and streptomycin.
The HPV16 E7, E6 immortalised human keratinocyte line
TFK 104 (Hawely-Nelson et al., 1989) was kindly supplied
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by K. Vousden (Ludwig Institute for Cancer Research, St
Mary's Hospital Medical SchooL London, UK). Cells were
maintained in keratinocyte SFM (Gibco), supplemented with
bovine pituitary extract (Clonetics), EGF (1Ongmlm') and
antibiotics. Human epidermal keratinocytes (HEKs) were
maintained in complete KGM (Clonetics).
BICR squamous cell carcinoma lines listed in Table I (K.
Edington et al., manuscript in preparation) were grown on
lethally irradiated NIH3T3 feeder cells (Rheinwald & Green,
1975) in DMEM with 10% FBS suppemnented with hydro-
cortisone (0.4jigm1'), glutamine and antibiotics. BICR 18
and BICR 22 grow optimally in 2% FBS.
EGFreceptor binding assay
['1I]EGF (Amersham, Cat. No. IM124, 50jCiml-') was
diluted to a specific activity of 0.05 iLCi ng-' with unlabelled
EGF (mouse, tissue culture grade, Sigma). The assay was
performed as described previously (Cowley et al., 1986).
Briefly, cells were plated at a density of 1 x I0O cells perwell
in 24-well tissue culture plates 24h before the assay. The
wells were washed three times with phosphate-buffered saline
(PBS), and incubated with labelled EGF in the presence or
absence of a 100-fold excess of unlabeled competitor in
0.5 ml of PBS with 1% BSA at room temperature for 1 h.
The range of competitor was 11 points between 1.0ng and
1 pg. Cells were then washed five times with ice-cold PBS/5%
BSA, solubilised in 1 ml of 1 N sodium hydroxide and the
amount of radioactivity determined in a gamma counter.
Counts were corrected for background and cell number and
data were analysed using th LIGAND program.
Binding ofEGFRI and EGF toplacental membrane
preparations
EGF and EGFR1 were radioiodinated using iodogen to
specific activities of40 and 250jICi g- 'respetively. Human
syncytiotrophoblast plasma membranes were prepared by
cold isotonic saline extraction (Smith et al., 1974). The assays
were performed in 96-well plates at 4-C in total volumes of
300id and the reagents were diluted in PBS/BSA (0.2%) for
the EGF assay and with 5% normal human serum for the
antibody assay. For the EGF assay 25,000 c.p.m. of
l'5IlEGF with a range of quantities of unlabelled EGF (18
points from 10 pg to 1 jLg) and for EGFR1, 50,000 c.p.m. of
['zIJEGFRI with a range ofquantities of unlabelled EGFR1
(11 points from 2ng to 2pg) were incubated with 10pg of
protein of placental membranes for 4h at 0-C. The mem-
branes were harvested and washed onto glass-fibre filters in a
multiple manifold vacuum harvester (LKB).
The radioactivity bound to the filters was detrmined with
a gamma counter. The data from duplicate experiments were
pooled and analysed with the LIGAND program to detrmine
receptor concentrations. The EGF binding data indicated
two classes of receptors with a combined apparent concentra-
tion of 2.3 pmol permg of placental membrane protein
+ 12%. The EGFRI binding gave only one class of receptor
with a concentration of 1.7 pmol permg of placental mem-
brane protein ± 9%.
EGFandEGFRJ immunohistochemistry on skin cryosections
EGF was biotinylated and detected on skin cryosections
(Reeves et al., 1993). EGFRI was detected using biotinylated
rabbit anti-mouse antibody, and non-immune mouse IgG2b
was used as a control for non-specific antibody binding.
(Reeves et al., 1993).
Quantitation ofEGFR on cryosections oftwnours
Cryosections were made from frozen tumour or xenograft
specimens (K. Edington, manuscript in preparation). The
sections were fixed in 50% acetone-PBS. Two sections from
each specimen were incubated with 200,000 c.p.m. of
['"I]EGFRI (specific activity of 2.5 x I0 c.p.m. mg-
EGFR1) for 3 h at 24'C in a volume of 100 tl of 50% calf
serum-PBS. Another section was treated similarly but a
200-fold excess of unlabelled EGFR1 was included in the
100 1. The sections were washed four times with 10% calf
serum-PBS, rinsed with water, air dried and placed in an
X-ray cassette and exposed to film for 16 h. The sections
were dipped in photographic emulsion (NTB-2 Kodak) and
exposed for sufficient time to generate between 100 and 400
grains per 100 Im2. The time ofexposure was estimated from
the density of the autoradiograph. Based on densitometric
scanning of the A431 cell pellet sections, the emulsions of
A431 require 4 h exposure to give an acceptable grain den-
sity. EJ cell pellets or normal sklin require 48 h. The silver
grains are counted per high-power field (HPF) which equals
6.67 x 10- mm2 with ten fields per slide using a
Joyce-Loebel Nikon Magiscan computer. Using this pro-
tocol, approximately equal numbers of grains were counted
per sample and expressed as the number of grains
100 zm-2 h-' exposure after subtracting the background
binding.
Resuls
EGFR levels on the SCCHN cell lines
Ligand-binding studies have been used to determine the
number of EGFRs on many different cell types. Previously it
has been detemined that normal keratinocytes grown in
tissue culture express 2.7 x i0 EGFRs per cell (Cowley et
al., 1984, 1986) or 5.5 x 106 EGFRs per cell if isolated from
gingival mucosa (Prime et al., 1994), while most SCC-derived
cell lines express around 106 EGFRs per cell. (Cowley et al.,
1984, 1986). We performed ['25I]EGF binding studies to
determine the number of EGFRs per cell on ten SCCHN,
two erythroplakia-derived cell lines, HPV16 E7, E6 immor-
talised foreskin keratinocytes (TFK104) and HEKs (Table I).
Eight of the cell lines express from 9 x 106 to 1.8 x 10'
EGFRs per cell, as do most other SCC-derived cell lines. One
of the tumour-derived cell lines, BICR19, and one of the
erythroplakia-derived cell lines, BICRE4, showed no increase
in EGFR expression compared with HEK, whik BICR18
and TFK104 showed a 2-fold increase in EGFRs compared
with HEKs. In BICR18, BICR19, BICRE4 and BICRE5 the
levels of EGFR were similar to those found in a recent study
(Primw et al., 1994). Thus, it is not esssential for all SCCHN-
derived cell lines to overexpress EGFR, nor is HPV16 E7
and E6 expression sufficient to cause more than a 2-fold
increase in EGFR expression.
Tabe I EGFR expresson on cell lines
Cel line
HEK
EJ
TFK104
A431
BICRE4
BICRES
BICR3
BICR6
BICR7
BICRIO
BICR16
BICR18
BICRl9
BICR22
BICR31
BICR56
BICR63
BICR68
Origin
Epdermal keratinocyte
Transitional cell carcinoma
Cerical keratinocyte
Carcinoma, vulva
Erytropia
Erythmplakia
Alveolu
Hypopharynx
Tongue
Buccal mucosa
Tongue
Laynx
Epidermis
Tongue
Tongue
Tongue
Tongue
Tongue
EGFR x IC$ per ceUl
0.2
0.2
0.4
1.8
0.2
0.3
1.4
1.8
1.2
0.9
1.6
0.4
0.2
1.0
1.2
1.3
0.9
1.0
The number ofEGFRspercell wasdetermied from ligand-binding
experimcnts as described in the Materials and methods section. The
BICR cel lines were derived by K. Edington and K. Parkinson
(unpubished data).EGFR EXPRESSION IN SCC 429
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Determination ofEGFR expression on twuour biopsy
specimens
To determine if EGFR overexpression on the cell lines
re the level of EGFR on the tumours from which they
were derived, we measured EGFR expression on tumour
cryosections. To quantitate the level of EGFR we used an
assay based on the competitive binding of the EGFR-speciflc
monoclonal antibody, EGFR1 (Waterfield et al., 1982), to
cryosections of tumour biopsy specimens (Gusterson et al.,
1984; Hendler & Ozanne, 1984; Ozanne et al., 1986; Hendier
et al., 1989). To demonstrate the specificity of EGFR1, we
observed the binding of EGF (Figure la and b) and EGFR1
(Figure Ic and d) to cryosections of normal skin. This dem-
onstrates that EGF and EGFR1 binding results in the same
pattern of staining. Immunohistochemical staining is not
quantitative. As the quantitation technique measures binding
of ['"I]EGFRI by the counting of silver grains following
autoradiography we wished to demonstrate that ['"IJEGFR1
resulted in the same pattern of binding to skin cryosections
as did unlabelled EGFR1. Cryosections ofskin were exposed
to ['"I]EGFRI in the presence or absence of an excess of
unlabelled EGFR1 (Figure le and f). The distribution of the
grains generated by radiolabelled EGFR1 was reminiscent of
the pattern of staining observed using biotinylated EGF or
EGFR1 detected immunohistocemiclly. Competition with
a 100-fold excess of unlabelled EGFRI demonstrated that
binding of ['"I]EGFRI was specific. These observations pro-
vided the basis for the quantitation of EGFR on biopsy
sections.
To demonstrate that the competitive binding assay was
quantitative we used several assays. Firstly, we determined
the concentration of EGFR in placental membrane prepara-
tions using either ['"IEGF or ['25]EGFR1 (Table H). EGFR
determined with both ligands was very similar. Secondly, we
compared the EGFR levels in cell nes with known numbers
of EGFR, A431, EJ and ZR-75-1 (Hend&er & Ozanne, 1984;
Ozanne et al., 1986), by counting the silver grains on cryosec-
tions of cell pellets of the cell lines (Table III). Scatchard
analysis indicated that A431 cells displayed approximately
eight times more EGFR than did EJ cells (Ozanne et a!.,
1986; Hendler et al., 1989), while ZR-75-1 cells have only
5 x 103 EGFRs per cell. EGFR1 binding as determined by
silver grain counts yielded similar results in terms of the
difference in binding between A431, EJ and ZR-75-1 cell
lines. Thirdly, we compared specific binding of EGFR1 and
EGF to cryosections of skin and EJ cell pellets. Ligand-
binding assays indicated that both HEKs and EJ cells have
around 2.5 x 101 EGFRs per cell. The EGFR1-EGF ratio
of grains on EJ cell pellets and skin was 1.5 and 1.6 respec-
tively (Table IV). For an assay to be comparable the binding
of EGFR1 to A431 and EJ cell pellets has to differ by 6- to
8-fold and the binding to frozen sections of skin must be
within the range of binding to EJ cells.
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Table H Quantitation of EGFR in placental membranes
Ligand pM EGFR mg- I protein
EGF 2.3 12%
EGFR1 1.7 9%
Bindingassays wereperformed onplacentalmembrane preparations.
Thedata represent theaverage oftwoindependent analysesasdescribed
in the Materials and methods section.
Table HI Binding of EGF and EGFR1 to cell lines
Cell line EGFR per cell Ratio to EJ EGFRI Ratio to EJ
A431 1.6x 106 8 26431 7.15
EJ 2.0x I0W 1 3698 1.0
ZR75 5 x 103 0.004 97 0.0026
['5I]EGFRl was used to determine the relative binding to cell lines
which differed in the level ofexpression ofEGFR. Numbers represent
specific binding of['"I]EGFRl to cryosections offrozen pellets of the
cells. The numbers represent the net silver grains per ten high-power
fields per hour ofeach section. Two cryosections ofeach cell line were
counted.
Table IV EGF and EGFR1 binding to cryosections of skin and EJ
cells
Section EGFRI Area CIA Hours C A h-'
EGFR1
EJ-1 2705 6.67 406 50 8.1
EJ-2 3254 6.67 488 50 9.8
Skin 1 1867 1.56 1197 194 6.2
Skin 2 887 0.75 1183 194 6.1
EGF
EJ-i 3286 6.67 493 % 5.1
Skin 1 1768 2.81 629 194 3.2
Ratio EJl/skin: EGFR1, 1.5; EGF, 1.6. The sections were treated as
described in the Materials and methods section. The numbers represent
grain counts per 100pm2. The non-specific binding was subtracted. The
exposure times were determined from 16 h exposures of autoradio-
graphs of the slides.
Table V Binding of EGFR1 to tumour and xenograft cryosections
Net Ratio of twnour Ratio of
Twnour counts to skin xenograft to ski
A431 22560 7.34 NA
Skin 3073 1.00 NA
BM 3780 1.23 NA
EJ 2854 0.93 NA
BICR3 3685 1.20 ND
BICR6 10037 3.27 3.46
BICR7 994 0.32 ND
BICR1O 4794 1.56 1.37
BICR16 3763 1.22 0.02
BICR18 5674 1.85 ND
BICR19 2714 0.88 0.07
BICR22 1090 0.35 0.89
Measurement of[']EGFRI binding to cryosections ofcell pellets for
the cell lines and biopsy specimens for skin, buccal mucosa (BM),
tumours and xenografts. All slides were exposed for 24 h, except A431.
which were normalised to 24 h from 4.5 h. The counts represent the net
silver grains per ten high-power fields.
Analysis of cryosections of the tumours (where available)
from which the BICR cell lines listed in Table I were derived
was performed using ['"I]EGFRI. Silver grains are localised
above normal skin (Figure ld), A431 (Figure 2) and EJ
(Figure 2) cell pellets and two of the tumours, BICR7 (Figure
2) and BICR22 (Figure 2). Quantitation of the grains indi-
cates that only two of the tumours displayed elevated levels
of EGFR, BICR6 and BICR18 (Table V). The increase in
EGFR expression in these tumours was higher than in nor-
mal skin, but the difference was not as great as that between
the cell lines and HEKs (Table I). The other tumours from
which cell lines were derived which have significant increases
in EGFR expression did not have a significant increase in
EGFR compared with normal skin. In fact one of them,
BICR22, displayed a decrease in the actual tumour, while the
cell line had a 5-fold increase. The cell lines which displayed
slightly elevated or HEK levels of EGFR, BICR18 and
BICRl9 respectively, were derived from tumours with slight-
ly elevated or skin levels of EGFR respectively. This
indicates that the EGFRl-binding assay does not give
artificially low levels of EGFR on the tumour sections.
The data above suggested that the increased expression of
EGFR observed on the BICR lines is a property of a subset
of tumour cells that grow in tissue culture and does not
reflect the state of expression in the original tumour. An
alternative explanation is that the potential to overexpress
the EGFR is suppressed in the tumours. To evaluate the
alternative explanation, we analysed xenograft tumours of
some of the cell lines isolated from nude mice. BICR6,
BICRIO and BICR22 expressed essentially the same level of
EGFR as they did in the tumour biopsy assays (Table V).
Binding of EGFR1 to the xenografts for BICR16 and
BICRl9 was almost non-existent, which may reflect the
highly differentiated state of these xenografts (data not
shown).
D6cssion
Using EGF ligand-binding assays we have demonstrated that
80% of a series of cell lines derived from SCCHN had a
significant increase in the level of expression of EGFR, con-
sistent with most previously reported studies (Cowley et al.,
1984, 1986; Ozanne et al., 1986; Hendler et al., 1989; Weich-
selbaum et al., 1989). In two of the cell lines, however,
EGFR expression was similar to that normally seen in HEKs
maintained in tissue culture. Two cell strains derived from
erythroplakias did not have elevated levels of EGFR. This
suggests that increased EGFR expression is not necessarily
associated with premalignant lesions as both lesions pro-
gressed to SCC within a year (K. Edington et al., manuscript
in preparation). Furthermore, both BICRE4 and BICRE5
are defective for terminal differentiation when placed in
suspension culture, which is consistent with their representing
premalignant keratinocytes. Recently it has been suggested
that expression of the EGFR and TGF-x expression is in-
creased in dysplastic lesions adjacent to SCCHN (Grandis &
Tweardy, 1993). The fact that the DOK cell line, derived
from such a lesion, displays a 3-fold increase in EGFR
expression (data not shown) as measured by ligand binding is
consistent with this observation. The BICRE4 and BICRE5
cell lines may represent a distinct pathway occurring before
malignancy has developed. Although the majority ofcell lines
were derived from late-stage tumours, metastases and recur-
rences, two cell lines, BICR3 and BICR63, were derived from
T2 stage tumours and were found to have elevated levels of
EGFR, suggesting that increased levels of expression are not
limited to cell lines derived from late-stage tumours. How-
ever, as one of the cell lines, BICR18, derived from a recur-
rent tumour, and another, BICR19, derived from a large and
aggressive skin tumour, had normal levels of EGFR expres-
sion, overexpression as detected in cultured cells is not neces-
sary for SCC progression.
The cell lines in this analysis were established and main-
tained using 3T3 feeder layers under culture conditions as
close as possible to those that would support the growth of
normal keratinocytes yet give optimal growth of the tumour
cells (Rheinwald & Beckett, 1981; K. Edington, manuscript
in preparation). This was done in an attempt to establish cell
lines representing the cells in the original tumour as closely as
possible. It is possible that even under these culture condi-
tions cells capable of overexpressing the EGFR were selected.
From the analysis of the EGFR1 binding to the cryosections
of the original tumours, no focal expression of the EGFR,
which would have suggested a subpopulation of cells with
high level of EGFR expression within the tumour, was
observed. Rather, the distribution of antibody seemed to be
inEGFR EXPRESSION IN SCC 431
relatively uniform. The observation that the xenograft
tumours displayed the same level of EGFR as the original
tumour, as seen particularly with BICR6, BICRIO and
BICR22, indicates that increased EGFR expression in the
cell lines reflected alterations in the regulation of expression
of the EGFR in culture rather than the outgrowth of high-
expressing subclones. The alterations in expression would be
A431- ~-
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specific properties of the tumours, since normal skin and
HEKs in tissue culture express proportionally similar levels
of EGFR. This demonstrates that simply placing
keratinocytes in tissue culture does not result in up-
regulation of the EGFR. Nor does it seem that immortalisa-
tion of cells by HPV16 E7 and E6, as in TFK104 cells, alters
the expression of the EGFR more than 2-fold, whereas most
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Figwe 2 EGFR on cryosections of tumours detected by ["UI]EGFRI. a, Assay performed with only ['"I]EGFRl. b, Assay
performed with ['25IlEGFRI in the presence of a 100-fold excess of unlabelled EGFRI. A431 sections were exposed for 4 h. All
others were exposed for 48 h,
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of the tumour-derived cell lines show a 5-fold increase in
EGFR expression in tissue culture compared with in vivo. A
similar conclusion can be drawn from the two erythroplakia-
derived cell strains, BICRE4 and BICRE5, which display at
most a 2-fold higher level of EGFR expression than
HEKs.
EGFR may have a dual role in tumorigenesis: to increase
the growth of the cells as a mitogen and to prevent terminal
differentiation (Rhienwald & Green. 1977). Studies with
antagonistic anti-EGFR monoclonal antibodies have demon-
strated that SCC cell lines require EGFR for growth (Masui
et al., 1984; Modjtahedi et al., 1993b). However, it is not
clear whether the antibodies induce differentiation of the
treated cells. None of the cell lines in this study that had
increased EGFR levels could be induced to terminally differ-
entiate in suspension cultures containing high concentrations
of calcium. BICR19, with low levels of EGFR, is the most
differentiated cell line (K. Edington, manuscript in prepara-
tion). However, elevated EGFR on the cell lines does not
prevent differentiation in xenografts as judged by the state of
BICR16 xenografts.
The BICR lines were also analysed for the expression of
other oncogenes. There were no detectable ras mutations
(Clark et al.. 1993). The cell lines do not display c-myc gene
amplifications (A. Malliri, S. Richards and B.W. Ozanne,
unpublished data), although expression at the mRNA level
may be increased slightly over that observed in HEKs. There
is a consistent increase in the level of cyclin Dl (CCNDI)
expression in these cell lines, with three of the cell lines
having significant amplifications of the CCNDI gene. (M.
Nikolic et al.. manuscript in preparation). The two cell lines.
BICR18 and BICR19, which have levels of EGFR approxi-
mating the levels observed in HEKs have elevated levels of
p34CYCDI protein expression, while two lines with elevated
levels of EGFR. BICR3 and BICR1O, display only modest
increases in p34cycD' expression. Therefore EGFR expression
and overexpression of p34 ycD' do not seem to be linked.
All of the tumour-derived cell lines have mutations in the
p53 gene (Burns et al., 1993) and none seems to have altera-
tions in the pRB105 gene product (Malliri, M. Nikolic. K.
Parkinson & B.W. Ozanne, unpublished data). Perhaps the
continuous signal from the EGFR and increased expression
of CCND1 obviate the need for pRB mutations. Alterna-
tively, pRB105 may not be important in the regulation of the
cell cycle of keratinocytes and therefore its inactivation is not
required.
Although the weight of the published studies indicates that
EGFR overexpression is common in squamous cell car-
cinomas both in vivo and in vitro, it appears that the level of
expression cannot be predicted from cell lines or tumours. It
may be that the potential to overexpress is more common
than the actual overexpression. Although recent data suggest
that EGFRs are necessary for the growth of SCC derived cell
lines (Modjtahedi et al., 1993b) it remains to be determined
what advantage overexpression affords the tumours, and
whether overexpression can be exploited to give better diag-
nosis or treatment of SCC.
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